Try 3 months for $3
Akorn

Akorn's expanded facility at 1222 W. Grand Ave. in Decatur is shown. 

DECATUR — The U.S. Food and Drug Administration sent a warning letter on Friday to Akorn Inc. after an inspection of the drugmaker's Decatur plant in April and May 2018, the company said Wednesday. 

The letter said a regulator found contaminants on sterile gloves and didn't have proper procedures for stopping contamination of drugs, Reuters reported

Akorn operates a plant at  1222 W. Grand Ave. and a packaging facility on Wyckles Road.

The Lake Forest-based company has 15 working days to respond.

"Akorn is committed to the highest standards of quality and compliance, and will continue to work collaboratively with the FDA to resolve all issues addressed in the warning letter," the company said in a statement. 

The drugmaker in recent years was the subject of an acquisition plan by Germany's Fresenius SE & Co KGaA, but the deal broke off amid questions about Akorn's regulatory compliance and a downturn in its business. A Delaware judge in October allowed Fresenius to abandon the plan.

CEO Raj Rai stepped down in December. 


Decatur-area business openings and closings

Subscribe to Breaking News

* I understand and agree that registration on or use of this site constitutes agreement to its user agreement and privacy policy.
0
0
0
0
0

Load comments